WO2014085486A2 - Methods and apparatus for the analysis of vitamin d metabolites - Google Patents

Methods and apparatus for the analysis of vitamin d metabolites Download PDF

Info

Publication number
WO2014085486A2
WO2014085486A2 PCT/US2013/072057 US2013072057W WO2014085486A2 WO 2014085486 A2 WO2014085486 A2 WO 2014085486A2 US 2013072057 W US2013072057 W US 2013072057W WO 2014085486 A2 WO2014085486 A2 WO 2014085486A2
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
metabolites
vit
calibrator
epi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/072057
Other languages
French (fr)
Other versions
WO2014085486A3 (en
WO2014085486A9 (en
Inventor
John Vukovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Waters Technologies Corp
Original Assignee
Waters Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waters Technologies Corp filed Critical Waters Technologies Corp
Priority to US14/648,197 priority Critical patent/US9719970B2/en
Publication of WO2014085486A2 publication Critical patent/WO2014085486A2/en
Publication of WO2014085486A3 publication Critical patent/WO2014085486A3/en
Publication of WO2014085486A9 publication Critical patent/WO2014085486A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/28—Control of physical parameters of the fluid carrier
    • G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0203—Solvent extraction of solids with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/40—Selective adsorption, e.g. chromatography characterised by the separation mechanism using supercritical fluid as mobile phase or eluent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers

Definitions

  • the present disclosure relates to C0 2 -based chromatography for use in the analysis and characterization of Vitamin D metabolites.
  • Vitamin D is a fat-soluble secosteroid that is responsible for intestinal absorption of calcium and phosphate.
  • the metabolic pathway for Vitamin D is complex and involves multiple mono-, di- and tri- hydroxy- forms of both Vitamin D 3 and Vitamin D 2 together with a number of epimer and "pre" isomers.
  • Vitamin D 3 is synthesized in the skin by the action of sun-light while a relatively small amount of vitamin D 2 is obtained from dietary sources. In some cases,
  • Vitamin D 2 might be taken as a supplement.
  • Vitamin D is converted to 25 -hydroxy vitamin D (abbreviated 25-OH-Vit-D) and current clinical practice uses the total serum 25-OH-Vit-D (i.e., 25-OH-Vit-D 3 plus 25-OH-Vit-D 2 ) levels to assess a person's Vitamin D status.
  • the 25-OH-Vit-D metabolite is then converted primarily in the kidneys to the hormonally active form 1,25-dihydroxy vitamin D (abbreviated l,25-(OH) 2 -Vit-D).
  • l,25-(OH) 2 -Vit-D circulates as a hormone in the blood and is responsible for regulating the concentration of calcium and phosphate in the bloodstream to promote healthy growth and remodeling of bone. 25-OH-Vit-D is also converted to l,25-(OH) 2 -Vit-D outside of the kidneys for other purposes, such as in the proliferation, differentiation, and apoptosis of cells.
  • Vitamin D also prove to be informative and relevant to the overall biological effect of Vitamin D.
  • the metabolite 24,25-(OH) 2 -Vit-D alone has no known biological activity, it represents the first step in the pathway to degrade 25-OH-Vit-D and is not routinely measured.
  • the enzyme responsible (Vitamin D 24-hydroxylase; CYP24A1) plays an important role in maintaining a normal ("sufficient") concentration of 25-OH-Vit-D. Too high a concentration of 25- OH-Vit-D can cause hypercalcemia and recent evidence suggests that at least some cases of Idiopathic Infantile Hypercalcemia (IIH) might be the result of natural polymorphisms in the CYP24A1 gene.
  • IIH Idiopathic Infantile Hypercalcemia
  • LC/MS analyses can quantitatively measure multiple analytes in the same analytical run. For example, in addition to analyzing 25-OH-Vit-D 2 and 25-OH-Vit-D 3 separately from C3-epi-25-OH- Vit-D 3 , an LC/MS method can also measure other Vitamin D metabolites (e.g., 24,25-(OH) 2 -Vit-D, l,25-(OH) 2 -Vit-D, etc.) in the same analysis. Such a multi-analyte analysis can provide a much more robust Vitamin D status. However, the analysis times of an LC/MS Vitamin D metabolite panel such as this becomes lengthy and impractical for routine laboratories.
  • Vitamin D metabolites e.g., 24,25-(OH) 2 -Vit-D, l,25-(OH) 2 -Vit-D, etc.
  • Vitamin D metabolites are present at low concentrations in serum and plasma (e.g., l,25-(OH) 2 -Vit-D, l,24,25-(OH) 3 -Vit-D, etc)
  • derivatization methods with Cookson- type reagents e.g., 4-phenyl-l,2,4-triazoline-3,5-dione (PTAD) and DMEQ-TAD (4-[2-(3,4-Dihydro- 6,7-dimethoxy-4-methyl-3-oxo-2-quinoxalinyl)ethyl]-3H-l,2,4-triazole-3,5(4H)-dione)
  • PTAD-linked Vitamin D metabolites derivatives have been used as a way to increase the sensitivity of detecting these metabolites by mass spectrometry.
  • Vitamin D metabolites Given the importance to accurately determine a person' s Vitamin D status, and to further understand the biological implications involved in the metabolic pathway for Vitamin D, e.g., being able to effectively monitor a panel of Vitamin D metabolites to diagnosis conditions at an early stage, there is a need to develop efficient chromatographic methods for the precise analysis of Vitamin D metabolites. For example, an efficient and precise method of analyzing Vitamin D metabolites, such as analyzing 25-OH-Vit-D 2 and 25-OH-Vit-D 3 separately from C3-epi-25-OH-Vit-D 3 , would prove useful in providing accurate measurements of a person's Vitamin D status.
  • Exemplary embodiments of the present disclosure are directed to rapid and efficient methods for the separation of Vitamin D metabolites.
  • the present disclosure is based, in part, on the discovery that a C0 2 -based chromatography system (e.g., ACQUITY UPC2 ® , Waters Corporation, Milford, MA) with features, such as, e.g., improved pressure stability, improved sample injection, and superior column chemistry, could reproducibly substantially resolve metabolites of Vitamin D.
  • a C0 2 -based chromatography system e.g., ACQUITY UPC2 ® , Waters Corporation, Milford, MA
  • features such as, e.g., improved pressure stability, improved sample injection, and superior column chemistry
  • Vitamin D status i.e., the total concentration of 25-OH-Vit-D in serum
  • commercially efficient and effective separations of certain Vitamin D metabolites, particularly C3-epi-25-OH-Vit-D 3 has not yet been achieved. Therefore, one aspect of the present disclosure provides an efficient and precise method for separating C3-epi-25-OH-Vit-D 3 using C0 2 -based chromatography.
  • the methods described herein comprise, at least in part, a C0 2 -based chromatography method for separating metabolites of Vitamin D, wherein at least a portion of the C0 2 used is in a supercritical state (or near supercritical state or STP).
  • the present disclosure also provides efficient and precise methods for separating low concentration metabolites (e.g., l,25-(OH) 2 -Vit-D or l,24,25-(OH) 3 -Vit-D) and derivatives thereof, metabolites involved in the determination of a person's Vitamin D status (25-OH-Vit-D 2 , 25-OH-Vit- D 3 , and C3-epi-25-OH-Vit-D 3 ), and enzymes and metabolites involved or implicated in Vitamin D metabolic processes.
  • low concentration metabolites e.g., l,25-(OH) 2 -Vit-D or l,24,25-(OH) 3 -Vit-D
  • metabolites involved in the determination of a person's Vitamin D status 25-OH-Vit-D 2 , 25-OH-Vit- D 3 , and C3-epi-25-OH-Vit-D 3
  • the C0 2 -based chromatography methods described herein minimize consumption of mobile phase solvents (e.g., methanol) thereby generating less waste for disposal and reducing the cost of analysis per sample. Also, because relatively short chromatographic run times (less than 5 minutes) are typically achieved with effective separation, the unique speed and resolution provided by the C0 2 -based chromatography methods described herein serve as a key element in developing high-throughput routine screening assays.
  • Figure 1 is an exemplary comparison of A) C0 2 -based chromatography /MS/MS; and B) UPLC/MS/MS separations of 25-OH-Vit-D 3 and C3-epi-25-OH-Vit-D 3 .
  • Figure 2 represents a rapid C0 2 -based chromatography /MS/MS analysis of Vitamin D metabolites using a BEH C18 column (1.7um, 2.1mm x 50mm).
  • Figure 3 represents a rapid C0 2 -based chromatography /MS/MS analysis of Vitamin D metabolites including the C3-epi-25-OH-Vit-D 3 using a fluorophenyl based column (1.7um, 2.1mm x 150mm).
  • the present disclosure provides a method of separating one or more metabolites of Vitamin D, comprising: placing a sample in a C0 2 -based chromatography system comprising a chromatography column; and eluting the sample by a gradient of organic solvent and a mobile phase fluid comprising C0 2 to substantially resolve the one or more metabolites.
  • the retention times for the one or more metabolites are less than 5 minutes, such as, e.g., from about 0.5 to about 3 minutes.
  • the chromatography column comprises particles having an average size of about 1.7, about 3.5, or about 5.0 microns. In another embodiment, the chromatography column comprises charged surface hybrid particles having a particle size of about 1.7 microns or about 3.5 microns.
  • the chromatography column is a fluorophenyl based chromatography column.
  • the one or more metabolites are selected from 25-OH- Vitamin D 3 ; 25- OH- Vitamin D 2 ; C3-epi-25 -OH- Vitamin D 3 ; 24, 25-dihydroxy- Vitamin D; la,25-dihydroxy- Vitamin D; 23(R), 25-dihydroxy- Vitamin D; 23(S), 25-dihydroxy- Vitamin D; 25,26-dihydroxy-Vitamin D; 4 ,25-dihydroxy- Vitamin D; calcitroic acid; and 1,24,25-trihydroxy-Vitamin-D.
  • the metabolites are 25-OH- Vitamin D 3 or C3-epi-25-OH- Vitamin D 3 .
  • the total elution times for the one or more metabolites is about 2 minutes on a chromatography column having a length of about 150 mm.
  • the C0 2 -based chromatography system comprises an operating system pressure of about 1,000 to about 9,000 psi and a backpressure of about 1,000 to about 9,000 psi.
  • the C0 2 -based chromatography system comprises one or more pumps for delivering a flow of the mobile phase fluid comprising C0 2 ; and an injection valve subsystem in fluidic communication with the one or more pumps and the chromatography column.
  • the injection valve subsystem comprises:
  • an auxiliary valve comprising:
  • an auxiliary valve stator comprising a first plurality of stator ports, in fluidic
  • an inject valve comprising:
  • auxiliary valve rotor is rotatable, relative to the auxiliary valve stator, between a plurality of discrete positions to form different fluidic passageways within the auxiliary valve; wherein the inject valve rotor is rotatable, relative to the inject valve stator, between a plurality of discrete positions to form different fluidic passageways within the inject valve, and wherein the respective positions of the auxiliary valve rotor and the inject valve rotor can be coordinated in such a manner as to allow the sample loop and the fluidic tubing to be pressurized to a high system pressure with the mobile phase fluid before they are placed in fluidic communication with the chromatography column.
  • the methods described herein may, further comprise obtaining a mass spectrometer signal of the one or more metabolites.
  • the present disclosure provides a method of separating C3- epi-25 -OH- Vitamin D 3 from a sample (e.g. Vitamin D or a biological sample from a human specimen), comprising:
  • the retention time for the C3-epi-25-OH- Vitamin D 3 ranges from about 0 to about 3 minutes, such as, e.g., from about 1 to about 2 minutes using the C0 2 -based
  • the present disclosure provides a method of separating low concentration Vitamin D metabolites (e.g., l,25-(OH) 2 -Vit-D or l,24,25-(OH) 3 -Vit-D), or derivatives thereof (e.g., derivatives generated by derivatisation methods such as with Cookson-type reagents), from a sample (e.g. Vitamin D), comprising:
  • a sample placed in a C0 2 -based chromatography system comprising a chromatography column (e.g., a fluorophenyl based column); and
  • a chromatography column e.g., a fluorophenyl based column
  • Kits for quantifying one or more metabolites of Vitamin D obtained by the methods of any methods described herein are also provided.
  • a kit may the comprise a first known quantity of a first calibrator, a second known quantity of a second calibrator, and optionally comprising one or more metabolites of Vitamin D, wherein the first known quantity and the second known quantity are different, and wherein the first calibrator, the second calibrator, and the one or more metabolites are each distinguishable in a single sample by mass spectrometry.
  • kits as described herein may also comprise instructions for:
  • the first calibrator and the second calibrator are each analogues, derivatives, metabolites, or related compounds of the one or more metabolites of Vitamin D.
  • Kits may also comprise a third known quantity of a third calibrator and a fourth known quantity of a fourth calibrator, wherein the third known quantity and the fourth known quantity are different, and wherein the first calibrator, the second calibrator, the third calibrator, the fourth calibrator, and the one or more metabolites of Vitamin D are each distinguishable in a single sample by mass spectrometry.
  • kits may also further comprise instructions for:
  • kits described herein may further comprise additional calibrators, such as, e.g., from 5 to 10 calibrators including both nonzero and blank calibrators. Instructions for obtaining a mass spectrometer signal and quantifying one or more metabolites of Vitamin D using these additional calibrators is also contemplated.
  • the kit contains 6 nonzero calibrators and a single blank calibrator.
  • kits described herein comprise one or more metabolites selected from 25-OH- Vitamin D 3 ; 25-OH- Vitamin D 2 ; C3-epi-25-OH- Vitamin D 3 ; 24, 25-dihydroxy- Vitamin D; la,25-dihydroxy- Vitamin D; 23(R), 25-dihydroxy- Vitamin D; 23(S), 25-dihydroxy- Vitamin D; 25, 26-dihydroxy- Vitamin D; calcitroic acid,4 ,25-dihydroxy- Vitamin D; C3-epi-l-a,25-dihydroxy- Vitamin D3, and 1,24,25-trihydroxy-Vitamin-D.
  • the metabolites are 25-OH- Vitamin D 3 or C3-epi-25-OH- Vitamin D 3 .
  • Computer readable mediums are also provided such that a computer readable medium may comprise computer executable instructions adapted to:
  • Vitamin D or derivatives thereof, as described herein (e.g., 25-OH- Vitamin D 3 , 25-OH- Vitamin D 2 , C3-epi-25-OH-Vitamin D 3 , l,25-(OH) 2 -Vit-D, or l,24,25-(OH) 3 -Vit-D, etc.);
  • obtaining a mass spectrometer signal comprising a first known quantity of a first calibrator, a second known quantity of a second calibrator, and optionally comprising one or more metabolites of Vitamin D, wherein the first known quantity and the second known quantity are different, and wherein the first calibrator, the second calibrator, and the one or more metabolites are each distinguishable in a single sample by mass spectrometry.
  • the computer readable medium may further comprise executable instructions adapted to quantifying one or more metabolites of Vitamin D in the single sample using the first calibrator signal, the second calibrator signal, and the signal of the one or more metabolites of Vitamin D. Examples
  • the autosampler (Acquity UPC2 ® Autosampler, Waters Corporation, Milford, MA) settings set forth in the Table 1 below were used in the Vitamin D metabolite analyses. Injection volumes were controlled by a sample list (MassLynxTM Software, Waters Corporation, Milford, MA) and recorded separately for each analysis.
  • Mass spectrometry data was obtained using a tandem quadrupole mass spectrometer (Xevo® TQD tandem quadrupole, Waters Corporation, Milford, MA), which was operated under the conditions set forth in Table 2.
  • Eluent from the C0 2 -based chromatography system (ACQUITY UPC2 ® , Waters Corporation, Milford, MA) was connected to the electrospray source via a splitter device supplied with a methanol make-up flow that was manually controlled.
  • the make-up flow rate was varied to optimise performance .
  • the optimum flow rate was between 0.1 and 0.8 mL/min.
  • Example 1 Separation and Analysis of 25-OH-Vitamin D 3 and C3-epi-25-OH-Vitamin D 3 .
  • Example 2 Separation and Analysis of 25-OH-Vitamin D 3 , 25-OH-Vitamin D 2 , and 1,25- ( OH) 2 -Vitamin D 3 .
  • Example 3 Separation and Analysis of 25-OH-Vitamin D 3 , 25-OH-Vitamin D 2 , l,25-(OH) 2 - Vitamin D 3 , and C3 -epi-25-OH-Vitamin D 3 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present disclosure relates to CO2-based chromatography for the efficient and precise separation of Vitamin D metabolites.

Description

METHODS AND APPARATUS FOR THE ANALYSIS OF VITAMIN D METABOLITES
Cross-Reference to Related Applications
[0001] This application claims priority to U.S. Provisional Application No. 61/731,883, filed November 30, 2012, which is incorporated herein by reference in its entirety.
Field of the Technology
[0002] The present disclosure relates to C02-based chromatography for use in the analysis and characterization of Vitamin D metabolites.
Background
[0003] Vitamin D is a fat-soluble secosteroid that is responsible for intestinal absorption of calcium and phosphate. The metabolic pathway for Vitamin D is complex and involves multiple mono-, di- and tri- hydroxy- forms of both Vitamin D3 and Vitamin D2 together with a number of epimer and "pre" isomers. In humans, Vitamin D3 is synthesized in the skin by the action of sun-light while a relatively small amount of vitamin D2 is obtained from dietary sources. In some cases,
pharmaceutical Vitamin D2 might be taken as a supplement. In the liver, Vitamin D is converted to 25 -hydroxy vitamin D (abbreviated 25-OH-Vit-D) and current clinical practice uses the total serum 25-OH-Vit-D (i.e., 25-OH-Vit-D3 plus 25-OH-Vit-D2) levels to assess a person's Vitamin D status. The 25-OH-Vit-D metabolite is then converted primarily in the kidneys to the hormonally active form 1,25-dihydroxy vitamin D (abbreviated l,25-(OH)2-Vit-D). l,25-(OH)2-Vit-D circulates as a hormone in the blood and is responsible for regulating the concentration of calcium and phosphate in the bloodstream to promote healthy growth and remodeling of bone. 25-OH-Vit-D is also converted to l,25-(OH)2-Vit-D outside of the kidneys for other purposes, such as in the proliferation, differentiation, and apoptosis of cells.
[0004] Other metabolites also prove to be informative and relevant to the overall biological effect of Vitamin D. For example, while the metabolite 24,25-(OH)2-Vit-D alone has no known biological activity, it represents the first step in the pathway to degrade 25-OH-Vit-D and is not routinely measured. The enzyme responsible (Vitamin D 24-hydroxylase; CYP24A1) plays an important role in maintaining a normal ("sufficient") concentration of 25-OH-Vit-D. Too high a concentration of 25- OH-Vit-D can cause hypercalcemia and recent evidence suggests that at least some cases of Idiopathic Infantile Hypercalcemia (IIH) might be the result of natural polymorphisms in the CYP24A1 gene.
[0005] It has been recently recognized that a structural isomer of 25-OH-Vit-D3 (the C3-epimer), which was thought only to be present in pediatric samples, is also present in adults. C3-epi-25-OH- Vit-D3 has no known biological relevance and it should therefore not be included in the measurement of Vitamin D status. Recent studies have highlighted that the majority of LC/MS/MS assays used by laboratories to report results to the Vitamin D External Quality Assurance Scheme (DEQAS) are not designed to differentiate between 25-OH-Vit-D3 and the C3-epimer. This is because the two isomers (25-OH-Vit-D3 and the C3-epimer) have identical chemical composition, molecular mass and MS/MS characteristics such that they cannot be separated solely on the basis of mass spectrometry. Instead, both isomers must first be separated from each other before they are introduced into the analyser region of the mass spectrometer. This can be achieved using conventional liquid chromatography. However, this difficult separation can take, if at all, from approximately 6 minutes to approximately 12 minutes per sample, which makes routine adoption of LC/MS based assays in a clinical laboratory impractical. Although some immunoassays are able to differentiate between 25-OH-Vit-D3 and the C3-epimer, there are other interferences and difficulties which result in most immunoassays having relatively poor assay characteristics (accuracy, precision, linearity etc.). Thus, at present there appears to be no single assay for Vitamin D status that provides all the desirable assay characteristics.
[0006] LC/MS analyses can quantitatively measure multiple analytes in the same analytical run. For example, in addition to analyzing 25-OH-Vit-D2 and 25-OH-Vit-D3 separately from C3-epi-25-OH- Vit-D3, an LC/MS method can also measure other Vitamin D metabolites (e.g., 24,25-(OH)2-Vit-D, l,25-(OH)2-Vit-D, etc.) in the same analysis. Such a multi-analyte analysis can provide a much more robust Vitamin D status. However, the analysis times of an LC/MS Vitamin D metabolite panel such as this becomes lengthy and impractical for routine laboratories.
[0007] In addition, because some Vitamin D metabolites are present at low concentrations in serum and plasma (e.g., l,25-(OH)2-Vit-D, l,24,25-(OH)3-Vit-D, etc), derivatization methods with Cookson- type reagents (e.g., 4-phenyl-l,2,4-triazoline-3,5-dione (PTAD) and DMEQ-TAD (4-[2-(3,4-Dihydro- 6,7-dimethoxy-4-methyl-3-oxo-2-quinoxalinyl)ethyl]-3H-l,2,4-triazole-3,5(4H)-dione)) to form, e.g., PTAD-linked Vitamin D metabolites derivatives, have been used as a way to increase the sensitivity of detecting these metabolites by mass spectrometry. However, this derivatization process results in pairs of isomeric derivatives for each analyte and may create inferences. Therefore, a significant challenge has been to resolve, in a short analysis time compatible with high sample throughput, these low concentration derivatives under current chromatographic techniques.
Summary
[0008] Given the importance to accurately determine a person' s Vitamin D status, and to further understand the biological implications involved in the metabolic pathway for Vitamin D, e.g., being able to effectively monitor a panel of Vitamin D metabolites to diagnosis conditions at an early stage, there is a need to develop efficient chromatographic methods for the precise analysis of Vitamin D metabolites. For example, an efficient and precise method of analyzing Vitamin D metabolites, such as analyzing 25-OH-Vit-D2 and 25-OH-Vit-D3 separately from C3-epi-25-OH-Vit-D3, would prove useful in providing accurate measurements of a person's Vitamin D status. Also, increasing the separation efficiency of low concentration metabolites (e.g., l,25-(OH)2-Vit-D or l,24,25-(OH)3-Vit- D) and/or derivatives thereof provides a superior advancement in the commercial analysis of Vitamin D metabolite panels.
[0009] Exemplary embodiments of the present disclosure are directed to rapid and efficient methods for the separation of Vitamin D metabolites. The present disclosure is based, in part, on the discovery that a C02-based chromatography system (e.g., ACQUITY UPC2®, Waters Corporation, Milford, MA) with features, such as, e.g., improved pressure stability, improved sample injection, and superior column chemistry, could reproducibly substantially resolve metabolites of Vitamin D.
[0010] Many clinical laboratories have developed routine LC/MS/MS assays to assess Vitamin D status (i.e., the total concentration of 25-OH-Vit-D in serum) to replace automated immunoassay techniques that can suffer from interference. However, commercially efficient and effective separations of certain Vitamin D metabolites, particularly C3-epi-25-OH-Vit-D3, has not yet been achieved. Therefore, one aspect of the present disclosure provides an efficient and precise method for separating C3-epi-25-OH-Vit-D3 using C02-based chromatography. The methods described herein comprise, at least in part, a C02-based chromatography method for separating metabolites of Vitamin D, wherein at least a portion of the C02 used is in a supercritical state (or near supercritical state or STP).
[0011] The present disclosure also provides efficient and precise methods for separating low concentration metabolites (e.g., l,25-(OH)2-Vit-D or l,24,25-(OH)3-Vit-D) and derivatives thereof, metabolites involved in the determination of a person's Vitamin D status (25-OH-Vit-D2, 25-OH-Vit- D3, and C3-epi-25-OH-Vit-D3), and enzymes and metabolites involved or implicated in Vitamin D metabolic processes.
[0012] In addition to other advantages, the C02-based chromatography methods described herein minimize consumption of mobile phase solvents (e.g., methanol) thereby generating less waste for disposal and reducing the cost of analysis per sample. Also, because relatively short chromatographic run times (less than 5 minutes) are typically achieved with effective separation, the unique speed and resolution provided by the C02-based chromatography methods described herein serve as a key element in developing high-throughput routine screening assays. Brief Description of the Drawings
[0013] The foregoing and other features and advantages provided by the present disclosure will be more fully understood from the following description of exemplary embodiments when read together with the accompanying drawings, in which:
[0014] Figure 1 is an exemplary comparison of A) C02-based chromatography /MS/MS; and B) UPLC/MS/MS separations of 25-OH-Vit-D3 and C3-epi-25-OH-Vit-D3.
[0015] Figure 2 represents a rapid C02-based chromatography /MS/MS analysis of Vitamin D metabolites using a BEH C18 column (1.7um, 2.1mm x 50mm).
[0016] Figure 3 represents a rapid C02-based chromatography /MS/MS analysis of Vitamin D metabolites including the C3-epi-25-OH-Vit-D3 using a fluorophenyl based column (1.7um, 2.1mm x 150mm).
Detailed Description of the Invention
[0017] In one embodiment, the present disclosure provides a method of separating one or more metabolites of Vitamin D, comprising: placing a sample in a C02-based chromatography system comprising a chromatography column; and eluting the sample by a gradient of organic solvent and a mobile phase fluid comprising C02 to substantially resolve the one or more metabolites. In some embodiments, the retention times for the one or more metabolites are less than 5 minutes, such as, e.g., from about 0.5 to about 3 minutes.
[0018] In one embodiment, the chromatography column comprises particles having an average size of about 1.7, about 3.5, or about 5.0 microns. In another embodiment, the chromatography column comprises charged surface hybrid particles having a particle size of about 1.7 microns or about 3.5 microns.
[0019] In one embodiment, the chromatography column is a fluorophenyl based chromatography column.
[0020] In one embodiment, the one or more metabolites are selected from 25-OH- Vitamin D3; 25- OH- Vitamin D2; C3-epi-25 -OH- Vitamin D3; 24, 25-dihydroxy- Vitamin D; la,25-dihydroxy- Vitamin D; 23(R), 25-dihydroxy- Vitamin D; 23(S), 25-dihydroxy- Vitamin D; 25,26-dihydroxy-Vitamin D; 4 ,25-dihydroxy- Vitamin D; calcitroic acid; and 1,24,25-trihydroxy-Vitamin-D. In another embodiment, the metabolites are 25-OH- Vitamin D3 or C3-epi-25-OH- Vitamin D3.
[0021] In one embodiment, the total elution times for the one or more metabolites is about 2 minutes on a chromatography column having a length of about 150 mm. [0022] In one embodiment, the C02-based chromatography system comprises an operating system pressure of about 1,000 to about 9,000 psi and a backpressure of about 1,000 to about 9,000 psi.
[0023] In one embodiment, the C02-based chromatography system comprises one or more pumps for delivering a flow of the mobile phase fluid comprising C02; and an injection valve subsystem in fluidic communication with the one or more pumps and the chromatography column.
[0024] As described herein, the injection valve subsystem comprises:
- an auxiliary valve comprising:
• an auxiliary valve stator, comprising a first plurality of stator ports, in fluidic
communication with the one or more pumps and the chromatography column; and
• an auxiliary valve rotor comprising a first plurality of grooves;
- an inject valve comprising:
• an inject valve stator comprising a second plurality of stator ports; and
• an inject valve rotor comprising a second plurality of grooves;
- a sample loop fluidically connected to the inject valve stator for receiving a sample slug to be introduced into a mobile phase fluid flow; and
- fluidic tubing fluidically connecting the auxiliary valve stator and the inject valve stator, wherein the auxiliary valve rotor is rotatable, relative to the auxiliary valve stator, between a plurality of discrete positions to form different fluidic passageways within the auxiliary valve; wherein the inject valve rotor is rotatable, relative to the inject valve stator, between a plurality of discrete positions to form different fluidic passageways within the inject valve, and wherein the respective positions of the auxiliary valve rotor and the inject valve rotor can be coordinated in such a manner as to allow the sample loop and the fluidic tubing to be pressurized to a high system pressure with the mobile phase fluid before they are placed in fluidic communication with the chromatography column.
[0025] The methods described herein may, further comprise obtaining a mass spectrometer signal of the one or more metabolites.
[0026] In other alternative embodiments, the present disclosure provides a method of separating C3- epi-25 -OH- Vitamin D3 from a sample (e.g. Vitamin D or a biological sample from a human specimen), comprising:
placing a sample in a C02-based chromatography system comprising a fluorophenyl based chromatography column; and
eluting the sample by a gradient of organic solvent and a mobile phase fluid comprising C02 to substantially resolve C3-epi-25-OH- Vitamin D3, wherein the retention time for C3-epi-25-OH- Vitamin D3 is less than 5 minutes and wherein the C02-based chromatography system is defined as above and optionally coupled to a mass spectrometer. [0027] In one embodiment, the retention time for the C3-epi-25-OH- Vitamin D3 ranges from about 0 to about 3 minutes, such as, e.g., from about 1 to about 2 minutes using the C02-based
chromatography system described above.
[0028] In another embodiment, the present disclosure provides a method of separating low concentration Vitamin D metabolites (e.g., l,25-(OH)2-Vit-D or l,24,25-(OH)3-Vit-D), or derivatives thereof (e.g., derivatives generated by derivatisation methods such as with Cookson-type reagents), from a sample (e.g. Vitamin D), comprising:
placing a sample in a C02-based chromatography system comprising a chromatography column (e.g., a fluorophenyl based column); and
eluting the sample by a gradient of organic solvent and a mobile phase fluid comprising C02 to substantially resolve the low concentration metabolites, or derivatives thereof, wherein the retention times for the low concentration metabolites, or derivatives thereof, is less than 5 minutes and wherein the C02-based chromatography system is defined as above and optionally coupled to a mass spectrometer.
[0029] Kits for quantifying one or more metabolites of Vitamin D obtained by the methods of any methods described herein are also provided. In one embodiment, a kit may the comprise a first known quantity of a first calibrator, a second known quantity of a second calibrator, and optionally comprising one or more metabolites of Vitamin D, wherein the first known quantity and the second known quantity are different, and wherein the first calibrator, the second calibrator, and the one or more metabolites are each distinguishable in a single sample by mass spectrometry.
[0030] The kits as described herein may also comprise instructions for:
(i) obtaining a mass spectrometer signal comprising a first calibrator signal, a second calibrator signal, and one or more metabolites of Vitamin D from the single sample comprising the first known quantity of the first calibrator, the second known quantity of the second calibrator, and optionally comprising one or more metabolites of Vitamin D; and
(ii) quantifying one or more metabolites of Vitamin D in the single sample using the first calibrator signal, the second calibrator signal, and the signal of the one or more metabolites of Vitamin D.
[0031] In some embodiments, the first calibrator and the second calibrator are each analogues, derivatives, metabolites, or related compounds of the one or more metabolites of Vitamin D.
[0032] Kits may also comprise a third known quantity of a third calibrator and a fourth known quantity of a fourth calibrator, wherein the third known quantity and the fourth known quantity are different, and wherein the first calibrator, the second calibrator, the third calibrator, the fourth calibrator, and the one or more metabolites of Vitamin D are each distinguishable in a single sample by mass spectrometry. These kits may also further comprise instructions for:
(i) obtaining a mass spectrometer signal comprising a third calibrator signal, a fourth calibrator signal, and one or more metabolites of Vitamin D from the single sample comprising the third known quantity of the third calibrator, the fourth known quantity of the fourth calibrator, and optionally comprising one or more metabolites of Vitamin D; and
(ii) quantifying one or more metabolites of Vitamin D in the single sample using the third calibrator signal, the fourth calibrator signal, and the signal of the one or more metabolites of Vitamin D.
[0033] The kits described herein may further comprise additional calibrators, such as, e.g., from 5 to 10 calibrators including both nonzero and blank calibrators. Instructions for obtaining a mass spectrometer signal and quantifying one or more metabolites of Vitamin D using these additional calibrators is also contemplated. In one exemplary embodiment, the kit contains 6 nonzero calibrators and a single blank calibrator.
[0034] In one embodiment, the kits described herein comprise one or more metabolites selected from 25-OH- Vitamin D3; 25-OH- Vitamin D2; C3-epi-25-OH- Vitamin D3; 24, 25-dihydroxy- Vitamin D; la,25-dihydroxy- Vitamin D; 23(R), 25-dihydroxy- Vitamin D; 23(S), 25-dihydroxy- Vitamin D; 25, 26-dihydroxy- Vitamin D; calcitroic acid,4 ,25-dihydroxy- Vitamin D; C3-epi-l-a,25-dihydroxy- Vitamin D3, and 1,24,25-trihydroxy-Vitamin-D. In other embodiments, the metabolites are 25-OH- Vitamin D3 or C3-epi-25-OH- Vitamin D3.
[0035] Computer readable mediums are also provided such that a computer readable medium may comprise computer executable instructions adapted to:
separating one or more metabolites of Vitamin D, or derivatives thereof, as described herein (e.g., 25-OH- Vitamin D3, 25-OH- Vitamin D2, C3-epi-25-OH-Vitamin D3, l,25-(OH)2-Vit-D, or l,24,25-(OH)3-Vit-D, etc.);
obtaining a mass spectrometer signal comprising a first known quantity of a first calibrator, a second known quantity of a second calibrator, and optionally comprising one or more metabolites of Vitamin D, wherein the first known quantity and the second known quantity are different, and wherein the first calibrator, the second calibrator, and the one or more metabolites are each distinguishable in a single sample by mass spectrometry.
[0036] The computer readable medium may further comprise executable instructions adapted to quantifying one or more metabolites of Vitamin D in the single sample using the first calibrator signal, the second calibrator signal, and the signal of the one or more metabolites of Vitamin D. Examples
[0037] General Conditions for the Analysis of Vitamin D Metabolites
[0038] The autosampler (Acquity UPC2® Autosampler, Waters Corporation, Milford, MA) settings set forth in the Table 1 below were used in the Vitamin D metabolite analyses. Injection volumes were controlled by a sample list (MassLynx™ Software, Waters Corporation, Milford, MA) and recorded separately for each analysis.
[0039] Table 1.
Figure imgf000009_0001
[0040] Mass spectrometry data was obtained using a tandem quadrupole mass spectrometer (Xevo® TQD tandem quadrupole, Waters Corporation, Milford, MA), which was operated under the conditions set forth in Table 2. Eluent from the C02-based chromatography system (ACQUITY UPC2®, Waters Corporation, Milford, MA) was connected to the electrospray source via a splitter device supplied with a methanol make-up flow that was manually controlled. The make-up flow rate was varied to optimise performance . The optimum flow rate was between 0.1 and 0.8 mL/min.
[0041] Table 2.
Figure imgf000010_0001
[0042] The multiple reaction monitoring transitions presented in Table 3 were used to monitor the Vitamin D metabolites.
[0043] Table 3.
Figure imgf000010_0002
'Because 25-OH-Vit-D3 and the C3-epimer have identical chemical composition, this MRM channel detected both analytes. [0044] Example 1: Separation and Analysis of 25-OH-Vitamin D3 and C3-epi-25-OH-Vitamin D3.
[0045] Pure standards of C3-epi-25-OH- Vitamin D3 and 25-OH-Vitamin D3 were dissolved in hexane and analysed in separate injections (2 uL per injection, approximately 300 pg of each analyte) using a C02-based chromatography system (e.g., ACQUITY UPC2®, Waters Corporation, Milford, MA). The C02-based chromatography system was fitted with a fluorophenyl based column
(ACQUITY UPC2™ CSH Fluoro-Phenyl Column, 130 A, 1.7 μηι, 2.1 mm X 150 mm, Waters Corporation, Milford, MA) and coupled to a tandem quadrupole mass spectrometer (Xevo® TQD tandem quadrupole, Waters Corporation, Milford, MA). The column was eluted at a flow rate of 1.0 mL/min using C02 mobile phase with a gradient of methanol from 5% to 20% over 1.5 min.
[0046] Retention times of approximately 1.2 and 1.4 minutes for 25-OH-Vitamin D3 and C3-epi-25- OH- Vitamin D3 respectively, with baseline resolution, is shown by Figure la where the two separate analyses are overlayed. The total run time of 2 minutes demonstrated substantial resolution at approximately 3 times faster when compared to conventional UPLC/MS/MS technologies. For comparison, Figure lb shows a human plasma sample that was spiked with C3-epi-25-OH- Vitamin D3 and subjected to liquid-liquid extraction before analysis using an existing UPLC/MS/MS method. Only partial resolution of the isomers is obtained in a 6 minute analysis.
[0047] Example 2: Separation and Analysis of 25-OH-Vitamin D3, 25-OH-Vitamin D2, and 1,25- ( OH)2-Vitamin D3.
[0048] Using a C18 UPLC chromatography column (ACQUITY UPLC® BEH CI 8 Column, 1.7um, 2.1mm x 50mm, Waters Corporation, Milford, MA), 25-OH-Vit-D2, 25-OH-Vit-D3, and 1,25- (OH)2Vit-D3 were eluted in less than 1.25 minutes using a C02-based chromatography system (e.g., ACQUITY UPC2®, Waters Corporation, Milford, MA). The column was eluted at a flow rate of 2.0mL/min using C02 mobile phase with a gradient of 2.5% to 20% methanol over 1.0 min.
Chromatographic peak widths of approximately 1.5 seconds at the base were observed and shown in Figure 2. This chromatograph shows that efficient separation of 25-OH-Vit-D2, 25-OH-Vit-D3, and l,25-(OH)2Vit-D3 can be achieved using a C02-based chromatography system fitted with a reverse phase CI 8 column.
[0049] Example 3: Separation and Analysis of 25-OH-Vitamin D3, 25-OH-Vitamin D2, l,25-(OH)2- Vitamin D3, and C3 -epi-25-OH-Vitamin D3.
[0050] Standards for 25-OH-Vitamin D2, 25-OH-Vitamin D3 and l,25-(OH) 2-Vitamin D3 were combined in hexane and 2 uL (approximately 300 pg of each analyte) was analyzed using a C02- based chromatography system (e.g., ACQUITY UPC2®, Waters Corporation, Milford, MA). The C02-based chromatography system was fitted with a fluorophenyl based column (ACQUITY UPC2™ CSH Fluoro-Phenyl Column, 13θΑ, 1.7 μηι, 2.1 mm X 150 mm, Waters Corporation, Milford, MA). The column was eluted at a flow rate of 1.0 mL/min using C02 mobile phase with a gradient of methanol from 5% to 20% over 1.5 min. In a separate analysis, 2 uL of a hexane solution of C3-epi- 25-OH- Vitamin D3 (approximately 300 pg) was analysed under the same conditions. As shown by Figure 3, when the chromatograms are overlayed, baseline resolution of 25-OH-Vit-D3 and C3-epi- 250H-Vit-D3, with 250H-Vit-D2 and l,25-(OH)2-Vit-D was observed with retention times up to approximately 2 min. It was also noted that additional optimization and the use of other column geometries could further enhance the speed of analysis.
[0051] The specification should be understood as disclosing and encompassing all possible permutations and combinations of the described aspects, embodiments, and examples unless the context indicates otherwise. One of ordinary skill in the art will appreciate that the invention can be practiced by other than the summarized and described aspect, embodiments, and examples, which are presented for purposes of illustration, and that the invention is limited only by the following claims.

Claims

What is claimed is:
1. A method of separating C3-epi-25-OH-Vit-D3 from a sample, comprising:
placing a sample in a C02-based chromatography system comprising a chromatography column; and
eluting the sample by a gradient of organic solvent and a mobile phase fluid comprising C02 to substantially resolve C3-epi-25-OH-Vit-D3.
PCT/US2013/072057 2012-11-30 2013-11-26 Methods and apparatus for the analysis of vitamin d metabolites Ceased WO2014085486A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/648,197 US9719970B2 (en) 2012-11-30 2013-11-26 Methods and apparatus for the analysis of vitamin D metabolites

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261731883P 2012-11-30 2012-11-30
US61/731,883 2012-11-30

Publications (3)

Publication Number Publication Date
WO2014085486A2 true WO2014085486A2 (en) 2014-06-05
WO2014085486A3 WO2014085486A3 (en) 2015-05-07
WO2014085486A9 WO2014085486A9 (en) 2015-05-28

Family

ID=50828593

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/072057 Ceased WO2014085486A2 (en) 2012-11-30 2013-11-26 Methods and apparatus for the analysis of vitamin d metabolites

Country Status (2)

Country Link
US (1) US9719970B2 (en)
WO (1) WO2014085486A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200186A1 (en) * 2014-06-27 2015-12-30 Siemens Healthcare Diagnostics Inc. Binding partners specific for vitamin d epimers in vitamin d assays
WO2015200178A1 (en) * 2014-06-27 2015-12-30 Siemens Healthcare Diagnostics Inc. Assays for vitamin d epimers
US9815907B2 (en) 2014-06-27 2017-11-14 Siemens Healthcare Diagnostics Inc. Binding partners specific for vitamin D epimers
US10106498B2 (en) 2014-06-27 2018-10-23 Siemens Healthcare Diagnostics Inc. Compositions relating to vitamin D
CN113627597A (en) * 2021-08-12 2021-11-09 上海大学 Countermeasure sample generation method and system based on general disturbance

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015040386A1 (en) * 2013-09-20 2015-03-26 Micromass Uk Limited Miniature ion source of fixed geometry
CN115078578A (en) * 2022-06-16 2022-09-20 广州市妇女儿童医疗中心 Serum vitamin D related metabolite detection method based on liquid chromatography-mass spectrometry
CN115494190A (en) * 2022-09-23 2022-12-20 浙江省检验检疫科学技术研究院 Method for simultaneously determining residual quantity of triadimefon and triadimenol enantiomer serving as metabolite of triadimefon in fruit and vegetable paste

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500432A (en) 1981-07-13 1985-02-19 Hewlett-Packard Company Automated sample concentrator for trace components
EP0311154B1 (en) 1987-04-10 1994-01-19 The Procter & Gamble Company Novel solid, nondigestible, fat-like compounds
US4797300A (en) 1987-04-10 1989-01-10 The Procter & Gamble Company Compositions containing novel solid, nondigestible, fat-like compounds
DE69108239T2 (en) 1990-04-26 1995-09-28 Procter & Gamble POLYESE FATTY ACID POLYESTER CONTAINING FATTY COMPOSITIONS.
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
US5792331A (en) 1996-12-19 1998-08-11 Dionex Corporation Preformed polymer coating process and product
BR9809150A (en) 1997-05-20 2000-08-01 Procter & Gamble Non-digestible flowable oil and process for production
US6982142B2 (en) 1997-12-01 2006-01-03 John Wayne Cancer Institute Methods for screening therapeutically effective agents
US20020182260A1 (en) 1998-05-29 2002-12-05 Cellegy Pharmaceuticals, Inc. Anti-inflammatory agents and methods for their preparation and use
EP0969001A3 (en) * 1998-06-23 2005-09-14 DSM IP Assets B.V. Process for the preparation of vitamin D3 and provitamin D3
US8133694B2 (en) * 1998-06-25 2012-03-13 Immundiagnostik Ag Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
US6632353B2 (en) * 2000-06-26 2003-10-14 Berger Instruments, Inc. Rapid sample collection in supercritical fluid chromatography
CN1220497C (en) 2001-09-18 2005-09-28 姜德勇 Antivirus antioxidizing active extract of proplis and its molecular inclusion compound
US20040043089A1 (en) 2002-09-04 2004-03-04 Rabie A-Bakr M Buguzhi agent and composition and methods of preparing and administering the same
WO2005039381A2 (en) 2003-05-05 2005-05-06 Drug Risk Solutions, L.L.C. Compositions and processes for analysis of pharmacologic agents in biological samples
MXPA06013137A (en) 2004-05-10 2007-05-16 Itesm Cancer cell growth inhibition by black bean (phaseolus vulgarisl) extracts.
US20060188397A1 (en) * 2005-01-07 2006-08-24 Lalit Chordia Method and apparatus for fraction collection
US7972867B2 (en) * 2005-04-06 2011-07-05 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites by mass spectrometry
CN100347156C (en) 2005-05-31 2007-11-07 台州市海盛化工有限公司 Vitamin D separating, purifying and crystallizing method
WO2007107545A1 (en) 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
US8232298B2 (en) 2006-03-22 2012-07-31 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and P53
RU2454415C9 (en) 2006-10-19 2013-02-27 Такеда Фармасьютикал Компани Лимитед Indole derivative
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
JPWO2008136428A1 (en) 2007-04-27 2010-07-29 武田薬品工業株式会社 Nitrogen-containing 5-membered heterocyclic compound
GB0710536D0 (en) 2007-06-01 2007-07-11 Veritron Ltd Plant extract and its therapeutic use
ES2534899T3 (en) 2007-08-06 2015-04-30 Janssen Pharmaceutica, N.V. Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
JP5438008B2 (en) 2007-09-21 2014-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Inhibitors of the interaction between MDM2 and p53
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
US7972868B2 (en) * 2007-11-28 2011-07-05 Quest Diagnostics Investments Incorporated Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry
EP2247933B1 (en) * 2008-02-25 2019-11-06 Waters Technologies Corporation Methods for the determination of the presence and quantity of vitamin d analogs in samples
CN101981013B (en) 2008-03-27 2013-05-29 詹森药业有限公司 Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors
ES2367760T3 (en) 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. DERIVATIVES OF QUINAZOLINONA AS INHIBITORS OF THE POLYMERIZATION OF THE TUBULIN.
RS53378B (en) 2008-04-10 2014-10-31 Takeda Pharmaceutical Company Limited CONDENSED RING UNITS AND THEIR USE
KR100921279B1 (en) 2008-07-31 2009-10-09 현대자동차주식회사 Brake booster
US20100236137A1 (en) 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
TWI476189B (en) 2009-02-04 2015-03-11 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
DK2429317T4 (en) 2009-04-17 2019-05-13 Natac Pharma S L Compositions with high levels of omega-3 fatty acids and with low levels of phytic acid
WO2011014122A1 (en) 2009-07-30 2011-02-03 The Thailand Research Fund System and method for extracting vitamin e from fatty acid distillates
ES2356217B1 (en) 2009-08-04 2012-02-13 Universidad De Salamanca METHOD FOR DETECTION OF RENAL DAMAGE.
GB201005315D0 (en) * 2010-03-29 2010-05-12 Micromass Ltd Seperation and quantitation of the C3-epimer of 250HD3 in serum using UPLC/MS/MS
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP2420228A1 (en) 2010-08-05 2012-02-22 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences AG Composition comprising retinol, a precursor or a reaction product of it and a plant extract from at least one chamomilla plant for the treatment of cancer
WO2012058619A1 (en) * 2010-10-29 2012-05-03 Cohesive Technologies Inc. Lc-ms configuration for purification and detection of analytes having a broad range of hydrophobicities
CN102558006B (en) 2012-02-27 2013-11-06 浙江大学 A method for separating vitamin D3 and tachysterol T3
WO2013173501A2 (en) * 2012-05-15 2013-11-21 Waters Technologies Corporation Chromatographic materials

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200186A1 (en) * 2014-06-27 2015-12-30 Siemens Healthcare Diagnostics Inc. Binding partners specific for vitamin d epimers in vitamin d assays
WO2015200178A1 (en) * 2014-06-27 2015-12-30 Siemens Healthcare Diagnostics Inc. Assays for vitamin d epimers
CN106661114A (en) * 2014-06-27 2017-05-10 西门子医疗保健诊断公司 Binding partners specific for vitamin d epimers in vitamin d assays
CN106661116A (en) * 2014-06-27 2017-05-10 西门子医疗保健诊断公司 Determination of vitamin D epimers
US9746484B2 (en) 2014-06-27 2017-08-29 Siemens Healthcare Diagnostics Inc. Binding partners specific for vitamin D epimers in vitamin D assays
US9804176B2 (en) 2014-06-27 2017-10-31 Siemens Healthcare Diagnostics Inc. Assays for vitamin D epimers
US9815907B2 (en) 2014-06-27 2017-11-14 Siemens Healthcare Diagnostics Inc. Binding partners specific for vitamin D epimers
US10106498B2 (en) 2014-06-27 2018-10-23 Siemens Healthcare Diagnostics Inc. Compositions relating to vitamin D
CN106661114B (en) * 2014-06-27 2019-01-29 西门子医疗保健诊断公司 Binding partners specific for vitamin D epimers in vitamin D assays
CN106661116B (en) * 2014-06-27 2019-04-30 西门子医疗保健诊断公司 Determination of vitamin D epimers
US10399938B2 (en) 2014-06-27 2019-09-03 Siemens Healthcare Diagnostics Inc. Compositions relating to vitamin D
CN113627597A (en) * 2021-08-12 2021-11-09 上海大学 Countermeasure sample generation method and system based on general disturbance
CN113627597B (en) * 2021-08-12 2023-10-13 上海大学 An adversarial sample generation method and system based on universal perturbation

Also Published As

Publication number Publication date
US9719970B2 (en) 2017-08-01
WO2014085486A3 (en) 2015-05-07
WO2014085486A9 (en) 2015-05-28
US20150308987A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US9719970B2 (en) Methods and apparatus for the analysis of vitamin D metabolites
US8729463B2 (en) Measurement of 25-hydroxyvitamin D3 and C3-epi-25-hydroxyvitamin D3
US20210239718A1 (en) Methods for detecting vitamin c by mass spectrometry
Levison et al. Quantification of fatty acid oxidation products using online high-performance liquid chromatography tandem mass spectrometry
CA2783708A1 (en) Mass spectrometry of steroidal compounds in multiplex samples
US20200166519A1 (en) Mass spectrometry method for detection and quantitation of metabolites
US20140273260A1 (en) Method for Determining Derivatized Analytes in A Separated Biological Fluid
CN110763788A (en) Kit and method for quantitatively detecting 5 fat-soluble vitamins in blood plasma
US11624737B2 (en) Methods for detecting lacosamide by mass spectrometry
Amir Hamzah et al. Advances in targeted liquid chromatography‐tandem mass spectrometry methods for endocannabinoid and N‐acylethanolamine quantification in biological matrices: A systematic review
Hellmuth et al. Aqueous normal phase chromatography improves quantification and qualification of homocysteine, cysteine and methionine by liquid chromatography–tandem mass spectrometry
Yang et al. High-throughput measurement of 25-hydroxyvitamin D by LC–MS/MS with separation of the C3-epimer interference for pediatric populations
Kozlov et al. Comprehensive single-platform lipidomic/metabolomic analysis using supercritical fluid chromatography–mass spectrometry
Pöhö et al. Comparison of liquid chromatography-mass spectrometry and direct infusion microchip electrospray ionization mass spectrometry in global metabolomics of cell samples
Bai et al. Quantitative determination of 8-isoprostaglandin F2α in human urine using microfluidic chip-based nano-liquid chromatography with on-chip sample enrichment and tandem mass spectrometry
Meunier et al. Four years of LC–MS/MS method for quantification of 25-hydroxyvitamin D (D2+ D3) for clinical practice
Jiang et al. Determination of molindone enantiomers in human plasma by high-performance liquid chromatography–tandem mass spectrometry using macrocyclic antibiotic chiral stationary phases
Kammerer et al. Achiral–chiral LC/LC–MS/MS coupling for determination of chiral discrimination effects in phenprocoumon metabolism
Ludovici et al. Principles, current applications, and future perspectives of liquid chromatography-mass spectrometry in clinical chemistry
Xiao et al. Development and validation of a liquid chromatography mass spectrometry method for simultaneous measurement of 25 (OH) D3, epi-25 (OH) D3, 25 (OH) D2, vitamin A, α-tocopherol, and γ-tocopherol
Li et al. A new method based on dispersive liquid–liquid microextraction for fat‐soluble vitamin determination in serum by LC–MS/MS
Jin et al. Overcome isomer interference in 1α, 25-dihydroxyvitamin D quantitation by liquid chromatography-tandem mass spectrometry
CN114487185A (en) Separation and identification method of cholesterol pathway
Desai et al. Advancements in liquid chromatography-mass spectrometry: method development and applications
Chambers et al. Simplifying peptide bioanalysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13858583

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14648197

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13858583

Country of ref document: EP

Kind code of ref document: A2